Progress toward commercialization continues with BLA submission for the VIASKIN Peanut Patch targeted for Q3 2026 and priority review requested. Clinical programs advance with completed toddler safety study recruitment and new infant studies, while funding is secured into Q3 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.